A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 7, Pages 1611-1621
Publisher
Springer Nature
Online
2016-11-28
DOI
10.1038/leu.2016.352
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
- (2015) T. R. W. Tipton et al. BLOOD
- Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
- (2015) A. H. Rook et al. BLOOD
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Immuno-regulatory antibodies for the treatment of cancer
- (2015) Jamie Honeychurch et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination
- (2015) Kavin Fatehchand et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The TLR7 agonist induces tumor regression both by promoting CD4+T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells
- (2015) Chenchen Wang et al. Oncotarget
- Update on obinutuzumab in the treatment of B-cell malignancies
- (2014) Tim Illidge et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Modes of action of TLR7 agonists in cancer therapy
- (2014) Sebastian Kobold et al. Immunotherapy
- Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice
- (2014) C Deligne et al. LEUKEMIA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
- (2013) J. Golay et al. BLOOD
- The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab
- (2013) Eleanor J. Cheadle et al. BRITISH JOURNAL OF HAEMATOLOGY
- GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present
- (2013) Delila J. Kern et al. LEUKEMIA & LYMPHOMA
- Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
- (2013) Frank Herting et al. LEUKEMIA & LYMPHOMA
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
- (2012) S. J. Dovedi et al. BLOOD
- Combination of Cyclophosphamide, Rituximab, and Intratumoral CpG Oligodeoxynucleotide Successfully Eradicates Established B cell Lymphoma
- (2012) David J. Betting et al. JOURNAL OF IMMUNOTHERAPY
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
- (2011) B. E. Wahlin et al. CLINICAL CANCER RESEARCH
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice
- (2011) Mayuka Horikawa et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
- (2011) S. Dalle et al. MOLECULAR CANCER THERAPEUTICS
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- Reciprocal Regulation of Activating and Inhibitory Fc Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy
- (2010) J. P. Butchar et al. CLINICAL CANCER RESEARCH
- Indirect Inhibition of Toll-like Receptor and Type I Interferon Responses by ITAM-Coupled Receptors and Integrins
- (2010) Lu Wang et al. IMMUNITY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
- (2009) S. P. Hilchey et al. BLOOD
- Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
- (2009) Jonathan W. Friedberg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma
- (2009) David J. Betting et al. JOURNAL OF IMMUNOTHERAPY
- Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)
- (2008) María Moreno et al. CANCER LETTERS
- TLR7 and TLR8 as targets in cancer therapy
- (2008) M P Schön et al. ONCOGENE
- NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
- (2007) Esther Moga et al. EXPERIMENTAL HEMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started